Press Releases Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
3.2 ^USD	+0.63%		+7.02%	-37.86%

04-15	Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	CI
04-15	Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	04-28	PR
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH	04-25	BU
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia	04-15	AQ
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights	04-15	AQ
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting	03-26	AQ
Reviva to Present at the UBS Virtual CNS Day	03-11	AQ
Reviva to Present at the 36th Annual ROTH Conference	03-07	AQ
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	02-20	AQ
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	02-06	AQ
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference	01-25	AQ
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones	01-04	AQ
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum	12-11	AQ
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference	11-30	AQ
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	11-16	AQ
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights	11-14	AQ
Thinking about buying stock in Fresh Vine Wine, Reviva Pharmaceuticals Holdings, Conduit Pharmaceuticals, Miromatrix Medical, or Eargo?	23-10-31	PR
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	23-10-30	AQ
Reviva Pharmaceuticals : Corporate Presentation	23-10-19	PU
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia	23-09-25	AQ
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	23-09-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Press Releases

Filters